Concert Pharmaceuticals Inc (CNCE) Shares Bought by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. lifted its holdings in shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 1.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 368,243 shares of the biotechnology company’s stock after acquiring an additional 6,576 shares during the period. Alyeska Investment Group L.P. owned 1.62% of Concert Pharmaceuticals worth $5,432,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of CNCE. SG Americas Securities LLC acquired a new stake in shares of Concert Pharmaceuticals during the 3rd quarter worth about $153,000. Alliancebernstein L.P. acquired a new stake in shares of Concert Pharmaceuticals during the 2nd quarter worth about $174,000. State of Wisconsin Investment Board acquired a new stake in shares of Concert Pharmaceuticals during the 2nd quarter worth about $181,000. The Manufacturers Life Insurance Company raised its position in shares of Concert Pharmaceuticals by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after acquiring an additional 287 shares in the last quarter. Finally, Airain ltd acquired a new stake in shares of Concert Pharmaceuticals during the 2nd quarter worth about $215,000. 65.36% of the stock is currently owned by institutional investors and hedge funds.

In other Concert Pharmaceuticals news, Director Ronald W. Barrett sold 14,156 shares of Concert Pharmaceuticals stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $24.70, for a total transaction of $349,653.20. Following the transaction, the director now owns 3,539 shares of the company’s stock, valued at $87,413.30. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Ryan Lynch sold 3,500 shares of Concert Pharmaceuticals stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $14.51, for a total value of $50,785.00. Following the transaction, the insider now directly owns 9,500 shares in the company, valued at approximately $137,845. The disclosure for this sale can be found here. Insiders own 10.10% of the company’s stock.

CNCE has been the topic of several research analyst reports. Zacks Investment Research raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 15th. ValuEngine raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Mizuho initiated coverage on Concert Pharmaceuticals in a research report on Thursday, October 26th. They set a “buy” rating and a $23.00 price target on the stock. TheStreet raised Concert Pharmaceuticals from a “d” rating to a “c+” rating in a research report on Wednesday, November 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Concert Pharmaceuticals in a research report on Friday, October 20th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Concert Pharmaceuticals has an average rating of “Buy” and an average target price of $23.00.

Concert Pharmaceuticals Inc (NASDAQ:CNCE) opened at $26.00 on Wednesday. Concert Pharmaceuticals Inc has a 12-month low of $7.11 and a 12-month high of $26.92.

TRADEMARK VIOLATION NOTICE: “Concert Pharmaceuticals Inc (CNCE) Shares Bought by Alyeska Investment Group L.P.” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2017/12/13/concert-pharmaceuticals-inc-cnce-shares-bought-by-alyeska-investment-group-l-p.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit